Karl D Lewis - JoVE Visualize

Showing results (71-80 of 72) with videos related to

Pageof 8

Sort By:

You have reached the last page of results.This site can display upto 72 results.

Journal for Immunotherapy of Cancer|October 2, 2021

Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrenceCraig L Slingluff, Karl D Lewis, Robert Andtbacka, et al.

Journal of the American Academy of Dermatology|September 8, 2024

A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6Brett G M Hughes, Alexander Guminski, Samantha Bowyer, et al.

Pageof 8

Showing results (71-80 of 72) with videos related to

Sort By:

Pageof 8

You have reached the last page of results.This site can display upto 72 results.

Journal for Immunotherapy of Cancer|October 2, 2021

Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrenceCraig L Slingluff, Karl D Lewis, Robert Andtbacka, et al.

Journal of the American Academy of Dermatology|September 8, 2024

A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6Brett G M Hughes, Alexander Guminski, Samantha Bowyer, et al.

Pageof 8